Monday, November 9, 2026

USD/CHF Bullish Momentum: 0.827% Up In The Last 24 Hours

USD/CHF Bullish Momentum: 0.827% Up In The Last 24 Hours

(VIANEWS) - USD/CHF (USDCHF) has been up by 0.8266% for the last session's close. At 17:09 EST on Sunday, 9 June, USD/CHF (USDCHF) is $0.90.

USD/CHF (USDCHF) Range

Concerning USD/CHF's daily highs and lows, it's 0.112% up from its trailing 24 hours low of $0.90 and 0.112% up from its trailing 24 hours high of $0.90.

USD/CHF's yearly highs and lows, it's 7.623% up from its 52-week low and 3.008% down from its 52-week high.

Volatility

USD/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.30%, a negative 0.07%, and a positive 0.30%, respectively.

USD/CHF's highest amplitude of average volatility was 0.42% (last week), 0.29% (last month), and 0.30% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CHF's Forex is considered to be overbought (>=80).

Previous days news about USD/CHF (USDCHF)

  • Usd/chf appears to be on backfoot amid subdued US dollar ahead of US NFP. According to FXStreet on Friday, 7 June, "The USD/CHF pair is slightly positive in Friday's Asian session but trades close to its crucial support of 0.8883. "
  • Usd/chf gains amid US labor market strength. According to FXStreet on Friday, 7 June, "The USD/CHF pair is seeing a boost after updated Nonfarm Payroll (NFP) figures from the US were released on Friday, surpassing market expectations. "

More news about USD/CHF (USDCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com